Sirio Pharma Working Capital to Net Assets Ratio
Sirio Pharma working capital to net assets ratio. Sirio Pharma (300791) has a Working Capital to Net Assets ratio of 36.0% as of June 2025. Working capital of CN¥959.34 Million (current assets of CN¥1.99 Billion minus current liabilities of CN¥1.03 Billion) is measured against net assets of CN¥2.66 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Sirio Pharma (2016–2024)
Working capital to net assets ratio of Sirio Pharma from 2016 to 2024. This chart shows how Sirio Pharma's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at 36.0%, reflecting working capital of CN¥959.34 Million against net assets of CN¥2.66 Billion CNY. See Sirio Pharma (300791) defensive interval to measure how many days the company can operate on defensive assets alone.
Sirio Pharma Working Capital to Net Assets Ratio by Year (2016–2024)
Sirio Pharma working capital to net assets ratio by year from 2016 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Sirio Pharma from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Sirio Pharma assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 45.4% | CN¥1.20 Billion | CN¥2.64 Billion | CN¥2.02 Billion | CN¥824.54 Million | ▼ -0.7 pp |
| 2023 | 46.1% | CN¥1.18 Billion | CN¥2.57 Billion | CN¥1.93 Billion | CN¥751.13 Million | ▼ -26.6 pp |
| 2022 | 72.7% | CN¥1.96 Billion | CN¥2.70 Billion | CN¥2.43 Billion | CN¥469.69 Million | ▲ +10.5 pp |
| 2021 | 62.2% | CN¥1.58 Billion | CN¥2.54 Billion | CN¥1.91 Billion | CN¥332.44 Million | ▲ +19.3 pp |
| 2020 | 42.9% | CN¥936.77 Million | CN¥2.18 Billion | CN¥1.32 Billion | CN¥387.06 Million | ▼ -9.3 pp |
| 2019 | 52.2% | CN¥1.02 Billion | CN¥1.95 Billion | CN¥1.32 Billion | CN¥301.38 Million | ▲ +46.2 pp |
| 2018 | 6.0% | CN¥47.20 Million | CN¥784.05 Million | CN¥569.14 Million | CN¥521.94 Million | ▼ -10.8 pp |
| 2017 | 16.8% | CN¥97.36 Million | CN¥580.20 Million | CN¥508.93 Million | CN¥411.57 Million | ▲ +10.7 pp |
| 2016 | 6.1% | CN¥28.13 Million | CN¥464.98 Million | CN¥820.40 Million | CN¥792.27 Million | — |